.The serum levels of NGF, IL-13 and TNF-a had a positive correlation ( r=0.506, p<0.01 
INTRODUCTION
SLE is a chronic autoimmune disease characterized by the deposition of immune complexes in different organs. The etiology of SLE is unknown, many predisposing factors playing an important role have been found, including genetic, environmental, infectious, and hormonal factors
(1) . In SLE, B cell hyperactivity and the presence of multiple autoantibodies were observed together with abnormalities in the Tcell immune response (2) . In addition, numerous abnormalities of the cytokine network have been described in patients suffering from SLE, some of them were shown to play a pivotal pathophysiological role in certain T cell, B cell or antigen-presenting cell dysfunctions characteristic of the disease (3) . Of these cytokines, nerve growth factor (NGF) has emerged as Th2 cytokine with an immunomodulatory effects (4) . NGF is the best-characterized member of neurotrophin family which include the brain-derived neurotrophic factor, neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) (5) . NGF through a specific tyrosine kinase receptor (TrKA) and a receptor belong to the TNF-α family promotes differentiation, growth and survival of peripheral and central neurons (6) . NGF receptors are expressed by several immune cells, suggesting the potential of responding to that neurotrophin (7) . There are extensive evidences that NGF is involved in the development and differentiation of immune cells.
It enhances lymphocytes proliferation in both B
and T cell population and it stimulates the production of IgM . The current study aimed to assess serum levels of NGF, IL-13 and TNF-α in Egyptian patients with SLE and to correlate their levels with the disease activity using SLE Disease Activity Index (SLEDAI). using commercial kit (Bio Source Europe S.A. Belgium).
SUBJECTS & METHODS

Statistical Analysis:
The results are presented as mean ± standard deviation (SD). Student ttest and Pearson's test were used for analysis of data. In all cases, P< 0.05 was considered significant. Results were analyzed with Epi-info version 6.02 computer package.
RESULTS
 Serum NGF: Significant increase (P<0.001) in serum NGF was present in all SLE patients as compared with the control group (Table 2) . Patients with active SLE showed significant increase (P < 0.001) in serum NGF as compared with patients with inactive disease (table 3) .  Serum IL-13 : Significant increase (P<0.001) in serum IL-13 was observed in all SLE patients as compared with the control groups ( Table 2) . Patients with active SLE showed significant increase (P<0.001) in IL-13 as compared with patients with inactive disease (table 3) .  Serum TNF-α: Significant increase (P<0.001) in serum TNF-α was observed in all SLE patients as compared with the control groups (Table 2) , while patients with active SLE showed significant increase (P<0.001) in TNF-a as compared with patients with inactive disease (table 3) . Cytokine levels and disease activity: Significant positive correlations were observed between serum NGF, IL-13 and TNF-α on one hand and SLEDAI on the other hand (r = 0.51, P<0.01),(r=0.83,P<0.001) and (r = 0.77, PO.01) respectively. Cytokine levels and some laboratory findings:
Positive correlations were observed between NGF, TNF-α and ESR, while significant negative correlations were observed between them and C 3 , C 4 . . The observation that the concentration of NGF is enhanced in the autoimmune disease, along with the evidence that cells of immune system are able to respond to and/or synthesize NGF has led to the hypothesis that NGF might be involved in autoimmune disease.
The results of the present study revealed that NGF was correlated significantly with SLEDAI indicating that NGF measurements could be a useful marker for the evaluation of the activity of the disease. At the same time, significant positive correlation was observed between serum NGF and ESR. On the other hand, significant negative correlation was present between NGF and serum levels of C 3 and C 4 . These observations are in agreement with those of Xu and Chen (24) who found that NGF levels were elevated in SLE patients with active disease as compared to patients with inactive disease and, also, they found significant correlations between serum NGF and SLEDAI ESR, serum C 3 so they suggested that NGF might be involved in the pathogenesis of SLE and closely correlated with disease activity .The source of elevated NGF in SLE is not clear, but many immune cells, activated in SLE, have the capacity to synthesize and release NGF. Thus, it seems likely that immune processes could be a source for NGF production. Moreover, proinflammatory cytokines such as TNF-α stimulates NGF production (35) . In the current study, elevated levels of TNF-α were present in SLE patients and significant positive correlation was observed between its levels and the levels of serum NGF suggesting that elevated TNF-α levels may lead to a continued increase of NGF production. That finding confirms the earlier results of the experimental study of Bennett et al. (36) who found that the synovium of transgenic arthritic mice overexpressing TNF-α contains high levels of NGF. reported that NGF is able to protect against autoimmune encephalomyelitis. Moreover, Braccilaudiero et al. (30) found that NGF, through the regulation of calcitonin gene-related peptide (CGRP) synthesis, could down regulate the immune response and the increased levels of NGF might represent a physiological mechanism to dampen the inflammatory response. However, it remains to be studied whether the use of NGF or anti-NGF antibodies may have some beneficial effects during the various stages of that disease.
IL-13, a sort of Th2 cytokine cloned recently, is mainly produced by activated T-cells (15) . It can stimulate B-cell proliferation and activation and induce Ig secretion, and plays an important role in humoral immune response. Our study found that serum IL-13 levels in active SLE patients were significantly higher than those of inactive SLE patients (P< 0.01), and the inactive patients also had significantly increased IL-13 levels as compared with normal controls (P<0.05), which were in agreement with the results of Gong et al.
(40) . These results indicated that abnormal transcriptional levels of IL-13 probably existed in SLE patients. Serum IL-13 levels in inactive patients were significantly higher than those of healthy controls, suggesting lymphocytes of inactive patients might come into being an active state. Kimata et al. (8) reported that NGF increased Ig production and lymphoblastoid Bcell lines proliferation in a dosedependent manner. Meanwhile, Brodie et al. (14) , also demonstrated that low-affinity NGF receptors (NGFR) were expressed on human B-lymphocytes, and NGF could regulate the action of B-cell through the specific receptors and then led to B-cell proliferation and Ig production. The present study also, proved that the levels of NGF in active SLE patients were significantly increased. It has been found that NGF can directly stimulate IL-13 secretion in immune cells. Furthermore, NGF can also promote the releasing of IL-4 and IL-5 in immune cells and increase the production of IgE and IgG . These findings suggest that NGF may magnify the action of Th2 cell and increase the releasing of IL-13. In the current study, it was found that the levels of serum IL-13,TNF-α and NGF had a positive correlation. At the same time, it was also observed that there was a close correlation between the levels of serum IL and, also, it constitutes an activation and maturation factor of dendritic cells which are essential in immune regulation and have, also, been implicated in autoimmunity in general, and SLE in particular (17) . In the current study, significant increases in serum levels of TNF-α were present in SLE patients, but higher levels of serum TNF-α were present in patients with active SLE as compared with patients with inactive SLE. The results of the present study agree with those of Aringer et al.
(43) , Miret et al. (44) and Studnicka-Benke et al. (45) . In their study on Egyptian patients with SLE, Sabry et al. (46) found high levels of TNF-α especially in patients with lupus nephritis.
In contrast to the present findings, Al-Janadi et al. (47) found increased levels of serum TNF-α only in a minority of patients with active SLE that correlated only with thrombocytopenia and these levels were within normal ranges in other clinical presentations .Of particular interest, Gomez et al. (48) found that TNF-α levels were diminished as a function of disease activity, suggesting a possible protective role in SLE. The lack of association between these data and the results of the present study could be explained by the hypothesis that SLE is a genetic disease (49) and it could be assumed that the difference in the genetics of different populations might be responsible for the difference in clinical presentation.
Significant positive correlation was observed between TNF-α and SLEDAI score indicating that TNF-α could be used as a sensitive marker for SLE disease activity. Moreover, a positive correlation was detected between TNF-α and NGF, a finding supports the notion that TNF-α is a potent inducer of NGF production.
In conclusion, NGF, IL-13 and TNF-α are involved in the pathogenesis of SLE and closely correlated with disease activity. The determination of serum NGF, IL-13 and TNF-α levels contribute to evaluating disease activity. 
